Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Medtronic
Baxter
Moodys
Dow
Express Scripts

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

Litigation Details for AbbVie Inc. v. Hikma Pharmaceutical Co Ltd. (D. Del. 2013)

See Plans and Pricing

« Back to Dashboard

AbbVie Inc. v. Hikma Pharmaceutical Co Ltd. (D. Del. 2013)

Docket   See Pricing Date Filed 2013-09-13
Court District Court, D. Delaware Date Terminated 2014-03-20
Cause 35:271 Patent Infringement Assigned To Gregory Moneta Sleet
Jury Demand None Referred To
Parties ABBVIE INC.; EXELA PHARMA SCIENCES LLC; HIKMA PHARMACEUTICAL CO LTD.; WEST-WARD PHARMACEUTICALS CORP.; WISCONSIN ALUMNI RESEARCH FOUNDATION
Patents 5,246,925; 5,597,815
Attorneys Benjamin J. Schladweiler; Derek James Fahnestock; Jeffrey S. Ward; Mary B. Graham; Wendy M. Ward
Firms Morris, Nichols, Arsht & Tunnell; Ross Aronstam & Moritz LLP
Link to Docket External link to docket
Small Molecule Drugs cited in AbbVie Inc. v. Hikma Pharmaceutical Co Ltd.
The small molecule drug covered by the patents cited in this case is   See Pricing .

Details for AbbVie Inc. v. Hikma Pharmaceutical Co Ltd. (D. Del. 2013)

Date Filed Document No. Description Snippet Link To Document
2013-09-13 1 action for infringement of U.S. Patent No. 5,597,815 (“the ’815 patent”). This action arises out of Hikma…civil action for patent infringement and declaratory judgment arising under the patent laws of the United…rights in the ʼ815 patent to WARF. AbbVie is the exclusive licensee of the ʼ815 patent. 19. … The ’815 patent expires on July 13, 2015. 20. The ’815 patent is listed in the FDA publication…’815 patent claims an approved use of paricalcitol as set forth in the FDA’s Orange Book, Patent Use External link to document
2013-09-13 4 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 5,597,815;. (els) (Entered: 09…2013 20 March 2014 1:13-cv-01557 830 Patent None District Court, D. Delaware External link to document
2013-10-25 6 hyperparathyroidism, and the patent directed to that indication, U.S. Patent 5,246,925, is expired. Since Hikma…combination of references that included U.S. Patent No. 5,246,925 to DeLuca et al. (hereinafter “DeLuca”).…wrongfully listed the patent in issue, U.S. Patent No. 5,597,815 (“the ‘815 patent”), in the Orange Book…of method-of-use patents under §271(e)(2)(A) to ‘controlling use patents,’ or patents that claim an approved…paricalcitol) injection product. The ‘815 patent is a method of use patent that does not cover the only approved External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Baxter
Boehringer Ingelheim
Merck
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.